anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,167,563. lndole derivatives. A. H. ROBINS CO. Inc. 6 Oct., 1966 [13 June, 1966], No. 25960/69. Divided out of 1,167,562. Heading C2C. Novel 3 - (2 - substituted ethyl) - indoles of the general formula wherein R is a hydrogen atom, a C 1-8  alkyl or C 1-9  alkanoyl group, a benzoyl group optionally substituted by fluorine, chlorine or bromine atoms or C 1-3  alkyl, C 1-3  alkoxy or trifluoromethyl groups, a phenyl group optionally substituted by fluorine, chlorine or bromine atoms or C 1-3  alkyl, C 1-3  alkoxy or trifluoromethyl groups, a phenyl-C 1-8  alkyl group or a C 3-9  cycloalkyl group; R 1  is a hydrogen atom, a C 1-8  alkyl group or a phenyl group optionally substituted as indicated above; R 2  is a hydrogen, fluorine, chlorine or bromine atom or a trifluoromethyl, hydroxyl, C 1-8  alkyl or C 1-8  alkoxy group or a phenyl-C 1-8  alkoxy group in which the phenyl moiety is optionally substituted as indicated above; R 3  is a hydrogen atom or a methyl group, no more than one methyl group being present as R 3 ; R 4  is a hydrogen atom, a C 1-8  alkyl group, a phenyl- C 1-8 alkyl group or a phenyl group optionally substituted as indicated above; A is a hydrogen atom, a C 1-9  alkanoyl group, a phenyl group optionally substituted as indicated above, a benzoyl group optionally substituted as indicated above or a phenyl-carbamoyl group in which the phenyl moiety is optionally substituted as indicated above; m is 0 or 1; n is 1, 2 or 3; p is 0 or 1, and when p is 0 the dotted line represents a carbon-carbon single bond; provided that when m is 0, one R 3  is a methyl group and/or R 4  is a C 1-8  alkyl or phenyl- C 1-8  alkyl group, and when m is 1, p is 0, and acid addition and quaternary ammonium salts thereof are prepared (a) by metal hydride reduction of a 1 - (indol-3-ylglyoxyloyl)-3-substituted pyrrolidine or -4-substituted piperidine of the general formula wherein R is a hydrogen atom, a C 1-8  alkyl group, a phenyl group optionally substituted as indicated above, a phenyl-C 1-8  alkyl group or a C 3-9  cycloalkyl group and A is a hydrogen atom or a phenyl group optionally substituted as indicated above; (b) by reaction of a 3-(2- hydroxyethyl)-indole of the general formula with a thionyl halide and reaction of the resulting 3.(2.haloethyl).-indole of the general formula wherein X is a halogen atom, with a heterocyclic amine of the general formula or (c) by dehydration of a 3-(2-substituted ethyl)-indole of the first general formula above wherein A is a hydrogen atom and p is I, followed optionally by salification. Novel 1 - (indol - 3 - ylglyoxyloyl) - 3 - substituted pyrrolidine or -4-substituted piperidines of the second general formula above are prepared by reaction of an indole-3-glyoxyloyl chloride of the general formula with a heterocyclic amine of the fifth general formula above. Pharmaceutical compositions having an anti- Parkinsonism effect comprise, as active ingredient, a 3-(2-substituted ethyl)-indole of the first general formula above or a pharmaceutically acceptable acid addition or quaternary ammonium salt thereof, together with a pharmaceutically acceptable carrier, and may be administered orally or parenterally.
Consecutive patients who presented with OGIB to the second people's hospital of GuangDong province between January 2003 and November 2008 were recruited. This study was approved by the ethical committee of the Second people's Hospital of GuangDong Province and was designed according to the CONSORT (Consolidated Standards of Reporting Trials) guidelines. All patients gave written informed consent before beginning the study. As a standard protocol, all patients presented with melena or hematochezia would receive at least 2 times upper gastrointestinal endoscopy before admission. Patients who had nondiagnostic upper GI endoscopy were also offered at least 2 times colonoscopy before admission. All gastrointestinal endoscopies were performed by experienced endoscopists (hanning Wang). OGIB were defined as patients who had nondiagnostic upper endoscopy and colonoscopy.

Patients who were \< 18 years, pregnant, in moribund conditions, or with terminal malignancy were excluded. Patients with contrast allergy and impaired renal function (serum creatinine \> 150 µmol/l) were also not eligible for this study. All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
Computerized 16-session intervention that is not believed to significantly modify bias. In this study, youth see stimuli personalized to their anxiety symptoms. During ICC sessions, youth see word-sentence pairs and are required to indicate whether word and sentence are related, but are not provided with feedback that aims to "train" a reduction in interpretation bias.
RATIONALE AND OBJECTIVES: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) radiomics had been used to evaluate lymphovascular invasion (LVI) in patients with breast cancer. However, no studies had explored the associations between features from delayed phase as well as multiphases DCE-MRI and the LVI status. Thus, we aimed to develop an efficient nomogram based on multiphases DCE-MRI to predict the LVI status in invasive (IBC) breast cancer patients.
MATERIALS AND METHODS: A retrospective analysis was conducted on preoperative clinical, pathological, and DCE-MRI data of 173 breast cancer patients. All patients were randomly assigned into training set (n=121) and validation set (n=52) in 7:3 ratio. The clinical, pathologic, and conventional MRI characteristics were then subjected to univariate and multivariate logistic regression analysis, and the clinical risk factors with P < 0.05 in the multivariate logistic regression were used to build clinical models. Different single-phase models (early phase, peak phase, and terminal phase), as well as a multiphases model integrating radiomics features from multiple phases, were established. Furthermore, a preoperative radiomics nomogram model was constructed by combining the rad-score of the multiphases model with clinicopathologic independent risk factors. Finally, the performance of the multiphases model, clinical model, and rad-score was compared using receiver operating characteristic (ROC) curves, area under the curve (AUC) values, and decision curve analysis (DCA). The clinical utility of the rad-score was evaluated using calibration curves, and Delong test was used to compare the differences in AUC values among the different models.
RESULTS: The axillary lymph nodes (ALN) status and Ki-67 had been identified as clinicopathologic independent predictors and a clinical model had been constructed. Image features that were extracted from the terminal phase of the DCE-MRI exhibited notably superior predictive performances compared to features from the other single phases. Particularly, in the multiphases model, terminal phase features were identified as potentially providing more predictive information. Among the nine features that were found to be associated with LVI in the multiphase model, one was derived from the early phase, two from the peak phase, and six from the terminal phase, indicating that terminal phase features contributed significantly more information towards predicting LVI. Evaluation of the nomogram performance revealed promising results in both the training set (AUCs: clinical model vs. multiphase model vs. nomogram=0.734 vs. 0.840 vs. 0.876) and the validation set (AUCs: clinical model vs. multiphase model vs. nomogram=0.765 vs. 0.753 vs. 0.832).
CONCLUSION: The DCE-MRI-based radiomics model demonstrated utility in predicting LVI status, features of the terminal phase offered more valuable information particularly. The preoperative radiomics nomogram enhanced the diagnostic capability of identifying LVI status in IBC patients, and might aid clinicians in making personalized treatment decisions.
Ethosuximide is the first drug reported to protect against age-related hearing loss, but its benefits are hampered by the pronounced side effects generated through systemic administration. We prepared a thermosensitive hydrogel containing ethosuximide-encapsulated multivesicular liposomes (ethosuximide-loaded MVLs-Gel) and evaluated its functional and histological effects on age-related hearing loss in C57BL/6J mice. The MVLs-Gel showed slow sustained-release characteristics up to over 120 h. After 8 weeks of treatment, compared to the oral systemic administration of ethosuximide, intratympanic ethosuximide-loaded MVLs-Gel injection dramatically reduced the loss of age-related spiral ganglion neurons in the apical turns of the mice (low-frequency regions, p < 0.05). Correspondingly, compared to the oral systemic administration group, the intratympanic ethosuximide-loaded MVLs-Gel injection group showed significantly lower auditory brainstem response threshold shifts at stimulus frequencies of 4, 8, and 16 kHz (low-and middle-frequency regions, p < 0.05). In conclusion, intratympanic ethosuximide-loaded MVLs-Gel injection can reach the apical turn of the cochlea, which is extremely difficult with oral systemic administration of the drug. The ethosuximide-loaded MVLs-Gel, as a novel intratympanic sustained-release drug delivery system, attenuated age-related hearing loss in C57BL/6J mice.
The recommended dose of Arformoterol Tartrate Inhalation Solution is one 15 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose of greater than 30 mcg (15 mcg twice daily) is not recommended.

Arformoterol Tartrate Inhalation Solution should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor (see the accompanying Patient Information). Arformoterol Tartrate Inhalation Solution should not be swallowed. Arformoterol Tartrate Inhalation Solution should be stored refrigerated in foil pouches. After opening the pouch, unused unit-dose vials should be returned to, and stored in, the pouch. An opened unit-dose vial should be used right away.

If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be reevaluated and additional therapeutic options should be considered.

No dose adjustment is required for patients with renal or hepatic impairment. However, since the clearance of Arformoterol Tartrate Inhalation Solution is prolonged in patients with hepatic impairment, they should be monitored closely.

The drug compatibility (physical and chemical), efficacy, and safety of Arformoterol Tartrate Inhalation Solution when mixed with other drugs in a nebulizer have not been established.

The safety and efficacy of Arformoterol Tartrate Inhalation Solution have been established in clinical trials when administered using the PARI LC ® Plus nebulizer (with a face mask or mouthpiece) and the PARI DURA NEB™ 3000 compressor. The safety and efficacy of Arformoterol Tartrate Inhalation Solution delivered from non-compressor based nebulizer systems have not been established.
The present invention relates to health preserving tea, more specifically to tea which mainly makes use of rare Chinese herbal medicines in Mountain Tai such as fleece-flower root, red ganoderma, lance asiabell root, rhizoma polygonati (usually called Mountain Tai four treasures) produced in Mountain Tai and is supplemented by other Chinese herbal medicines. The present invention is prepared from (by weight ratio) 0.7 to 1 g of fleece-flower root, 0.6 to 1 g of red ganoderma, 0.5 to 1 g of lance asiabell root, 0.3 to 1 g of rhizoma polygonati, 0.3 to 0.7 g of morindae officinalis and 0.5 to 1 g of broomrape which are packed into small bags. After being infused for 10 minutes in boiled water, the health preserving tea can be drunk. The present invention mainly integrates physiological function regulation, toxin in vivo removal, mental stress relief, kidney nourishment, yang enhancement and sexual function improvement. Therefore, the present invention has the functions of nourishing kidneys, enhancing yang, raising sexual function, enhancing physical quality, improving the function of sugar metabolism and raising immunity, has good curative effect and health care effect on hypertension, diabetes, prostatitis, mastopathy, etc. and has the characteristics of reliable medical performance, stable curative effect, no toxic or side effect, etc.
DR30303 injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a traditional Chinese medicine preparation for brightening skin colors, and a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention is prepared from ginseng, astragalus and rheum officinale by the traditional Chinese medicine concept of 'tonifying qi and blood externally, removing fire and eliminating evil'. Wherein, the ginseng has the effects of tonifying qi, promoting the production of body fluid, smoothening blood vessels, maintaining beauty and keeping young; astragalus mongholicus has effects of consolidating exterior and expelling toxin, and promoting the circulation of muscle and skin striae, and dispelling pathogenic qi in exterior; rhubarb, radix et rhizoma Rhei purges heat and cools blood, removes stasis and dredges menstruation, and promotes aging to bring about new, and the medicines are introduced to the exterior to remove putrefaction and promote tissue regeneration. The whole formula has the effects of tonifying qi, promoting the production of body fluid, smoothing blood vessels, moisturizing skin, removing necrotic tissue and promoting tissue regeneration. The traditional Chinese medicine composition provided by the invention can obviously reduce the pigmentation of facial skin and lighten the skin color. In addition, the traditional Chinese medicine preparation provided by the invention can effectively remove volatile oil and other dry components in traditional Chinese medicine components, so that the medicine property of the tonic medicine is milder. The invention provides another way to lighten skin color for individuals with individual differences.
The invention provides an external hot-compress weight-reducing medicine for postpartum obesity. The external hot-compress weight-reducing medicine is prepared by the following steps of: taking 1-3g of Chinese angelica, 1-5g of leonurus japonicus, 1-3g of rhizoma alismatis, 1-3g of betel nut, 1-3g of nutgrass galingale rhizome, 1-3g of fennel, 1-3g of folium sennae and 0.5-1g of borneol, grinding the materials into powder and mixing. Since the weight-reducing medicine is used by hot compressing and massaging the abdominal and the umbilical parts, the ingredients of the medicine are permeated into the subcutaneous fat under the action of heat so as to play a role in reducing the fat, simultaneously adjust the digestion function of a human body, promote the circulation of qi, excrete water, eliminate swelling and further achieve the effect of reducing the weight. Since the weight-reducing medicine is used by hot compressing and massaging outside the human body, the ingredients of the medicine do not participate in the metabolism of the human body, and also can not be accumulated in the human body, so that the medicine can not generate the influence on lactated infants, thus being safe and effective. By experiments, the weight-reducing effect is obvious and no side effect is caused. The external hot-compress weight-reducing medicine is suitable for being applied as a medicine for reducing the weight of a parturient with postpartum obesity.
Enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care (DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B. Both the groups will receive appropriate management for their morbidities as per existing NICU protocols. Both the groups will be followed up till 37 weeks of gestation where in their neurobehavioral assessment will be performed using Neurobehavioural assessment of preterm infants score.

In both the groups all the baseline data regarding antenatal factors will be recorded in a predesigned proforma such as age, gravid, Gestational age, Chorioamnionitis, Prenatal steroids, Multiple pregnancy, maternal comorbidities (preeclampsia, gestational diabetes mellitus), mode of delivery etc.
Flu-like signs and symptoms have been reported with use of ZYCLARA and may accompany, or even precede, local skin reactions [see Adverse Reactions (6)] . Signs and symptoms may include fatigue, nausea, fever, myalgias, arthralgias, malaise and chills. Concomitant use of ZYCLARA and any other imiquimod products may increase the risk for and severity of systemic reactions. 

Lymphadenopathy occurred in 2% of subjects with AK treated with ZYCLARA, 3.75% and in 3% of subjects treated with ZYCLARA, 2.5% and in no patients in the vehicle arm [see Adverse Reactions (6.1)]. This reaction resolved in all subjects by 4 weeks after completion of treatment. 

Consider an interruption of dosing if systemic reactions occur .
The present invention relates to a novel gene, CaSm, that is highly expressed in cancer tissues and cell lines, especially pancreatic cancer. The full length cDNA of CaSm encodes a protein of 133 amino acids. CaSm contains the two Sm motifs found in the common snRNP proteins, with the greatest homology to the Sm G protein (60 % similarity). The present invention further encompasses CaSm peptides, fusion proteins, host cell expression systems, antibodies to CaSm, antisense CaSM molecules, and compounds that modulate CaSm gene expression or CaSm activity. Antisense CaSm RNA is able to alter the transformed phenotype of pancreatic cancer cells by reducing their ability to form large colonies in soft agar when compared to untransfected cells. The present invention also encompasses methods for disease diagnosis, drug screening and the treatment of cancer.
The invention relates to a medical apparatus including a support structure. The structure contains or supports medicament acceptable carrier or excipient. The carrier or the excipient contains one or more therapeutic agents or substance. The carrier preferably comprises a coating layer on the surface. The coating layer includes a therapeutic substance, such as a medicament. A support structure suitable for the medical apparatus includes but is not limited to a coronary artery stand, a peripheral stent, a vessel, an arterial-intravenous implant, a circuitous implant, and a medicament delivery sacculus for the vasculature. The medicament suitable for the invention includes but is not limited to a compound of general formula (I). The medicament can be used together with another medicament including a medicament selected from antiproliferative, anti-platelet agent, anti-inflammatory medicament, anti-embolism medicament, cytotoxin, a medicament for inhibiting combining of cell factor or chemical factor, cell de-differentiation inhibitor, anti-lipaedemic medicament, matrix metalloproteinase inhibitor, medicament for inhibiting cell or combination of these medicaments.
Intensive chemotherapy protocols are the most commonly used treatments in childhood cancers. While these protocols increase recovery rates, they may also cause some undesirable side effects. Nausea and vomiting are one of the most common toxic side effects associated with chemotherapy. The aim of this study was to develop an interactive mobile application and to investigate the effect of this application on the management of nausea and vomiting symptoms by using it during chemotherapy treatment.

The study will be conducted with 61 children between 8-18 years of age who received chemotherapy in the Pediatric Hematology-Oncology Clinic at Trakya University Health Research and Application Center. The study was planned as a randomized controlled study. Data will be collected with the "Information Form" and "Rhodes Adapted Rhodes Nausea and Vomiting Scale for Children". The interactive mobile application will be downloaded to the phones of the experimental group and this device will be used from the first chemotherapy day to the seventh day. While the experimental group evaluates their nausea and vomiting via mobile application twice a day, every 12 hours for one week, the control group will record their nausea and vomiting experiences in the "Nausea and Vomiting Diary". While the experimental group will be able to use the mobile application which consists of diverting attention, routine control will be applied to the control group.
BACKGROUND: The timing of antiviral therapy for chronic hepatitis B (CHB) patients with normal alanine transaminase (ALT) or aged < 30 years is still undetermined. We aimed to elucidate the correlation between liver histology, age, and ALT level in CHB patients and analyze the histological characteristics of the liver among patients with persistently normal ALT or aged < 30 years.
METHODS: A retrospective analysis was conducted on 697 treatment-naive CHB patients. Liver biopsies were performed, and significant histological damage was defined as the grade of liver inflammation ≥ G2 and/or fibrosis ≥ S2 based on the Scheuer scoring system.
RESULTS: The liver inflammation grades and fibrosis stages correlated positively with age, ALT, AST, GGT levels and negatively with the counts of PLT (all p < 0.050) in HBeAg-positive patients. Higher ALT levels and lower PLT counts were independently associated with significant liver inflammation and fibrosis in both HBeAg-positive and HBeAg-negative patients. Furthermore, among those with persistently normal ALT levels, the incidence of significant liver inflammation and fibrosis were 66.1% and 53.7% in HBeAg-positive groups, and 63.0% and 55.5% in HBeAg-negative groups. Moreover, there was no significant difference in the prevalence of significant liver damage between patients aged < 30 years and those aged ≥ 30 years, in both HBeAg-positive (≥ G2 or ≥ S2: 63.8% vs. 75.8%, p = 0.276) and HBeAg-negative (≥ G2 or ≥ S2: 65.9% vs. 72.5%, p = 0.504) groups, among patients with persistently normal ALT levels.
CONCLUSIONS: A considerable proportion of CHB patients with persistently normal ALT, including those below the age of 30 years, exhibited significant histological damage. This highlights the importance of initiating early antiviral therapy for HBV-infected individuals, even in the absence of elevated ALT levels.